Litigation Details for ASTRAZENECA AB v. MYLAN PHARMACEUTICALS INC. (D.N.J. 2015)
✉ Email this page to a colleague
ASTRAZENECA AB v. MYLAN PHARMACEUTICALS INC. (D.N.J. 2015)
| Docket | ⤷ Sign Up | Date Filed | 2015-05-15 |
| Court | District Court, D. New Jersey | Date Terminated | 2018-01-30 |
| Cause | 35:271 Patent Infringement | Assigned To | Freda L. Wolfson |
| Jury Demand | Referred To | Douglas Arpert | |
| Patents | 8,536,206; 8,604,064; 8,618,142 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in ASTRAZENECA AB v. MYLAN PHARMACEUTICALS INC.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for ASTRAZENECA AB v. MYLAN PHARMACEUTICALS INC. (D.N.J. 2015)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2016-01-11 | 40 | U.S. Patent Nos. 5,712,298, 8,536,206, 8,604,064, and 8,618,142 (collectively, the “Patents-in-Suit…Act for a drug claimed in a patent or the use of which is claimed in a patent[.]” …collectively, “Plaintiffs”), bring this Hatch-Waxman Act patent infringement suit against Defendant Mylan Pharmaceuticals…Dalisresp, and that Defendant will infringe the Patents-in-Suit pursuant to 35 U.S.C. § 271(a), (b), and…litigates in this district, having been a party to 41 patent infringement cases since 2010, the majority of | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
